<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38959327</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>754</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>eadk3295</StartPage><MedlinePgn>eadk3295</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.adk3295</ELocationID><Abstract><AbstractText>The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, and T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort of 24 participants at time points ranging from 27 to 910 days after acute SARS-CoV-2 infection using the radiopharmaceutical agent [<sup>18</sup>F]F-AraG, a selective tracer that allows for anatomical quantitation of activated T lymphocytes. Tracer uptake in the postacute COVID-19 group, which included those with and without continuing symptoms, was higher compared with prepandemic controls in many regions, including the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall. T cell activation in the spinal cord and gut wall was associated with the presence of LC symptoms. In addition, tracer uptake in lung tissue was higher in those with persistent pulmonary symptoms specifically. Increased T cell activation in these tissues was also observed in many individuals without LC. Given the high [<sup>18</sup>F]F-AraG uptake detected in the gut, we obtained colorectal tissue for in situ hybridization of SARS-CoV-2 RNA and immunohistochemical studies in a subset of five participants with LC symptoms. We identified intracellular SARS-CoV-2 single-stranded spike protein-encoding RNA in rectosigmoid lamina propria tissue in all five participants and double-stranded spike protein-encoding RNA in three participants up to 676 days after initial COVID-19, suggesting that tissue viral persistence could be associated with long-term immunologic perturbations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryder</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0008-4873-2493</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flavell</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-8694-1199</Identifier><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yingbing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levi</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0846-0795</Identifier><AffiliationInfo><Affiliation>CellSight Technologies, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaFranchi</LastName><ForeName>Brian H</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0009-0007-2019-3494</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-9834-8616</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-7193-0617</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asare</LastName><ForeName>Kofi A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslam</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szabo</LastName><ForeName>Gyula</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0493-8437</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5112-4220</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deswal</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Antonio E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buitrago</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0005-3934-6361</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1415-0766</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Uttam</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-8642-1468</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalhuisen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9132-0496</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasquez</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-7165-5739</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7612-3352</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><Identifier Source="ORCID">0000-0002-3427-6043</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nitasha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1369-3283</Identifier><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0002-9773-3256</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambhir</LastName><ForeName>Aruna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CellSight Technologies, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somsouk</LastName><ForeName>Ma</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6116-3645</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Youngho</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5908-6636</Identifier><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0001-6371-747X</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laszik</LastName><ForeName>Zoltan G</ForeName><Initials>ZG</Initials><Identifier Source="ORCID">0000-0003-0511-8764</Identifier><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VanBrocklin</LastName><ForeName>Henry F</ForeName><Initials>HF</Initials><Identifier Source="ORCID">0000-0003-2849-0841</Identifier><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI145806</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS136197</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="Y">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of Interest. MJP reports consulting fees for Gilead Sciences and AstraZeneca and research support from Aerium Therapeutics, outside the submitted work. SGD reports consulting for Enanta Pharmaceuticals and Pfizer and research support from Aerium Therapeutics, outside the submitted work. TJH reports consulting fees for Roche and Regeneron outside the submitted work. JL is employed by CellSight Technologies, holds CellSight stock options, and holds patents relating to [18F]F-AraG (Methods and Materials for Making PET Radiotracers, US20220370648A1; Methods and Materials for Using [18F]F-AraG in Cardiac Imaging, US20230309833A1). AG was employed by CellSight Technologies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38959327</ArticleId><ArticleId IdType="mid">NIHMS2008125</ArticleId><ArticleId IdType="pmc">PMC11337933</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adk3295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY, Post-acute COVID-19 syndrome. Nat Med 27, 601&#x2013;615 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ, Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B, High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259&#x2013;264 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention COVID Data Tracker. US Department of Health and Human Services, CDC. (https://covid.cdc.gov/covid-data-tracker).</Citation></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, Borrell LN, Nash D, The Epidemiology of Long Coronavirus Disease in US Adults. Clin Infect Dis 76, 1636&#x2013;1645 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S, An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26, 1636&#x2013;1643 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A, Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A, Yale IT, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND, Dela Cruz C, Farhadian S, Ko AI, Omer SB, Iwasaki A, Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, Anderson KG, Li J, Yang F, Duncombe CJ, McCulloch DJ, Rostomily C, Troisch P, Zhou J, Mackay S, DeGottardi Q, May DH, Taniguchi R, Gittelman RM, Klinger M, Snyder TM, Roper R, Wojciechowska G, Murray K, Edmark R, Evans S, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Algren HA, Berrington WR, Wallick JA, Cochran RA, Micikas ME, Unit IS-SC-B, Wrin T, Petropoulos CJ, Cole HR, Fischer TD, Wei W, Hoon DSB, Price ND, Subramanian N, Hill JA, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Chu H, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR, Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895 e820 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, Arechiga VM, Zepeda V, Sun K, Shao S, Hill C, Arreguin MI, Lu S, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Kornak J, Henrich TJ, Martin JN, Deeks SG, Hsue PY, Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight 7, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9220849</ArticleId><ArticleId IdType="pubmed">35389890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, Hong KY, Rasmussen H, Miller GE, Bishehsari F, Balk RA, Moy JN, Hoh R, Lu S, Goldman AR, Tang HY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Kelly JD, Wasse H, Martin JN, Liu Q, Keshavarzian A, Landay A, Deeks SG, Henrich TJ, Abdel-Mohsen M, Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kappaB signaling. JCI Insight 7, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9675436</ArticleId><ArticleId IdType="pubmed">36134654</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, Donatelli J, Thanh C, Takahashi S, Hakim J, Turcios K, Janson O, Hoh R, Tai V, Hernandez Y, Fehrman EA, Spinelli MA, Gandhi M, Trinh L, Wrin T, Petropoulos CJ, Aweeka FT, Rodriguez-Barraquer I, Kelly JD, Martin JN, Deeks SG, Greenhouse B, Rutishauser RL, Henrich TJ, Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 36, 109518 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, Forman CA, Munter SE, Hoh R, Tai V, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Greenhouse B, Hunt PW, Hsue PY, Martin JN, Daniel Kelly J, Glidden DV, Deeks SG, Henrich TJ, Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 224, 1839&#x2013;1848 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Sans HM, Forman CA, Nylander AN, Ho HE, Lu S, Goldberg SA, Hoh R, Tai V, Munter SE, Chenna A, Yee BC, Winslow JW, Petropoulos CJ, Martin JN, Kelly JD, Durstenfeld MS, Hsue PY, Hunt PW, Greene M, Chow FC, Hellmuth J, Henrich TJ, Glidden DV, Deeks SG, Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. Neurol Neuroimmunol Neuroinflamm 9, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210548</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, Tabachnikova A, Tabacof L, Malik AA, Kamath K, Greene K, Monteiro VS, Pena-Hernandez M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Silva J, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng TJ, Xu L, Yildirim I, Krumholz HM, Shon J, Medzhitov R, Omer SB, van Dijk D, Ring AM, Putrino D, Iwasaki A, Distinguishing features of Long COVID identified through immune profiling. medRxiv, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, Chee RS, Yeo NK, Tambyah P, Pada S, Tan SY, Ding Y, Renia L, Leo YS, Ng LFP, Lye DC, Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infect Dis 8, ofab156 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Holl JI, Gekle M, Mikolajczyk R, Binder M, The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 3, 100663 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD, Matthews GV, Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23, 210&#x2013;216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, Andrew A, Young KC, Ma T, Hoh R, Anglin K, Huang B, Argueta U, Lopez M, Valdivieso D, Asare K, Deveau TM, Munter SE, Ibrahim R, Standker L, Lu S, Goldberg SA, Lee SA, Lynch KL, Kelly JD, Martin JN, Munch J, Deeks SG, Henrich TJ, Roan NR, Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol, (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Bonham KS, Anam FA, Walker TA, Faliti CE, Ishii Y, Kaminski CY, Ruunstrom MC, Cooper KR, Truong AD, Dixit AN, Han JE, Ramonell RP, Haddad NS, Rudolph ME, Yalavarthi S, Betin V, Natoli T, Navaz S, Jenks SA, Zuo Y, Knight JS, Khosroshahi A, Lee FE, Sanz I, Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun 14, 4201 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="pubmed">37452024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E, Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol 21, 190 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB, Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol 21, 148 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Prevalence of readily detected amyloid blood clots in &#x2018;unclotted&#x2019; Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol 19, 193 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB, Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 20, 172 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C, Bruningk SC, Hoch T, Fan B, Muzio G, Thompson RC, Ceglarek L, Meledin R, Westermann P, Emmenegger M, Taeschler P, Zurbuchen Y, Pons M, Menges D, Ballouz T, Cervia-Hasler S, Adamo S, Merad M, Charney AW, Puhan M, Brodin P, Nilsson J, Aguzzi A, Raeber ME, Messner CB, Beckmann ND, Borgwardt K, Boyman O, Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science 383, eadg7942 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ, Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens 10, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ, Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest 133, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodansky A, Wang CY, Saxena A, Mitchell A, Takahashi S, Anglin K, Huang B, Hoh R, Lu S, Goldberg SA, Romero J, Tran B, Kirtikar R, Grebe H, So M, Greenhouse B, Durstenfeld MS, Hsue PY, Hellmuth J, Kelly JD, Martin JN, Anderson MS, Deeks SG, Henrich TJ, DeRisi JL, Peluso MJ, Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long COVID patients. medRxiv, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10393220</ArticleId><ArticleId IdType="pubmed">37288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Haddad NS, Anam FA, Rudolph ME, Walker TA, Truong AD, Dixit AN, Han JE, Cabrera-Mora M, Runnstrom MC, Bugrovsky R, Hom J, Connolly EC, Albizua I, Javia V, Cashman KS, Nguyen DC, Kyu S, Singh Saini A, Piazza M, Tipton CM, Khosroshahi A, Gibson G, Martin GS, Maier CL, Esper A, Jenks SA, Lee FE, Sanz I, Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 611, 139&#x2013;147 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, Zhang K, Patel Z, Salter B, Yuen ACY, Lau KS, Cowbrough B, Radford K, Huang C, Kjarsgaard M, Dvorkin-Gheva A, Smith J, Li QZ, Waserman S, Ryerson CJ, Nair P, Ho T, Balakrishnan N, Nazy I, Bowdish DME, Svenningsen S, Carlsten C, Mukherjee M, Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J 61, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F, Menzer S, Jacob J, Roessler M, Seifert M, Kind B, Konig C, Schulte C, Buschmann T, Hertle D, Ballesteros P, Bassler S, Bertele B, Bitterer T, Riederer C, Sobik F, Reitzle L, Scheidt-Nave C, Schmitt J, Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10497688</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CJ, Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine 56, 101783 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hagglof T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O&#x2019;Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC, Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639&#x2013;644 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, Kimpel J, Adolph TE, Tilg H, Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology 163, 495&#x2013;506 e498 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, Park RM, Han A, Schmidtke DT, Verma R, Jacobson KB, Parsonnet J, Bonilla HF, Singh U, Pinsky BA, Andrews JR, Jagannathan P, Bhatt AS, Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) 3, 371&#x2013;387 e379 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR, Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis 76, e487&#x2013;e490 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ, Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil RJ, Tabatabai A, Soherwardi S, McCurdy MT, Consortium NC-A, Peterson KE, Cohen JI, de Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS, SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758&#x2013;763 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY, Chen EX, Nerurkar SN, Loong S, Cheow PC, Chan CY, Koh YX, Tan TT, Kalimuddin S, Tai WMD, Ng JL, Low JG, Yeong J, Lim KH, Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 71, 226&#x2013;229 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, Krishnamachary B, Ram AK, Kumar A, Chen L, Chalise P, Dhillon NK, Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol 95, e28568 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, Goldberg SA, Hoh R, Chen JY, Martinez EO, Kelly JD, Martin JN, Goetzl EJ, SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol 91, 772&#x2013;781 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, Bach K, Boribong BP, Buggert M, Cherry S, Chertow DS, Davies HE, Dupont CL, Deeks SG, Eimer W, Ely EW, Fasano A, Freire M, Geng LN, Griffin DE, Henrich TJ, Iwasaki A, Izquierdo-Garcia D, Locci M, Mehandru S, Painter MM, Peluso MJ, Pretorius E, Price DA, Putrino D, Scheuermann RH, Tan GS, Tanzi RE, VanBrocklin HF, Yonker LM, Wherry EJ, SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 24, 1616&#x2013;1627 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB, Force RMPT, Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 12, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich TJ, Hsue PY, VanBrocklin H, Seeing Is Believing: Nuclear Imaging of HIV Persistence. Front Immunol 10, 2077 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6751256</ArticleId><ArticleId IdType="pubmed">31572355</ArticleId></ArticleIdList></Reference><Reference><Citation>Henrich TJ, Jones T, Beckford-Vera D, Price PM, VanBrocklin HF, Total-Body PET Imaging in Infectious Diseases. PET Clin 16, 89&#x2013;97 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10270309</ArticleId><ArticleId IdType="pubmed">33160926</ArticleId></ArticleIdList></Reference><Reference><Citation>Verger A, Barthel H, Tolboom N, Fraioli F, Cecchin D, Albert NL, van Berckel B, Boellaard R, Brendel M, Ekmekcioglu O, Semah F, Traub-Weidinger T, van de Weehaeghe D, Morbelli S, Guedj E, 2-[(18)F]-FDG PET for imaging brain involvement in patients with long COVID: perspective of the EANM Neuroimaging Committee. Eur J Nucl Med Mol Imaging 49, 3599&#x2013;3606 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286958</ArticleId><ArticleId IdType="pubmed">35840817</ArticleId></ArticleIdList></Reference><Reference><Citation>Debs P, Khalili N, Solnes L, Al-Zaghal A, Sair HI, Yedavalli V, Luna LP, Post-COVID-19 Brain [(18)F] FDG-PET Findings: A Retrospective Single-Center Study in the United States. AJNR Am J Neuroradiol 44, 517&#x2013;522 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171380</ArticleId><ArticleId IdType="pubmed">37105680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci R, Cuffaro L, Capozza A, Rosci C, Maiorana N, Groppo E, Reitano MR, Poletti B, Ticozzi N, Tagliabue L, Silani V, Priori A, Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. J Neurol 270, 1823&#x2013;1834 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873215</ArticleId><ArticleId IdType="pubmed">36692636</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini AL, Carli G, Kiferle L, Piersanti P, Palumbo P, Morbelli S, Calcagni ML, Perani D, Sestini S, Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging 50, 90&#x2013;102 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388976</ArticleId><ArticleId IdType="pubmed">35984451</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LL, van de Burgt A, Smit F, Audhoe RS, de Boer SM, van Velden FHP, de Geus-Oei LF, Investigating the potential added value of [ 18 F]FDG-PET/CT in long COVID patients with persistent symptoms: a proof of concept study. Nucl Med Commun 44, 495&#x2013;501 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171287</ArticleId><ArticleId IdType="pubmed">36951877</ArticleId></ArticleIdList></Reference><Reference><Citation>Goehringer F, Bruyere A, Doyen M, Bevilacqua S, Charmillon A, Heyer S, Verger A, Brain (18)F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur J Nucl Med Mol Imaging 50, 1084&#x2013;1089 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9628394</ArticleId><ArticleId IdType="pubmed">36322190</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Nardo L, Spencer BA, Abdelhafez YG, Li EJ, Omidvari N, Chaudhari AJ, Badawi RD, Jones T, Cherry SR, Wang G, Total-Body Multiparametric PET Quantification of (18) F-FDG Delivery and Metabolism in the Study of COVID-19 Recovery. medRxiv, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10626370</ArticleId><ArticleId IdType="pubmed">37591539</ArticleId></ArticleIdList></Reference><Reference><Citation>Omidvari N, Jones T, Price PM, Ferre AL, Lu J, Abdelhafez YG, Sen F, Cohen SH, Schmiedehausen K, Badawi RD, Shacklett BL, Wilson I, Cherry SR, First-in-human immunoPET imaging of COVID-19 convalescent patients using dynamic total-body PET and a CD8-targeted minibody. medRxiv, (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10569706</ArticleId><ArticleId IdType="pubmed">37824612</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, Jivan S, Huynh TL, Blecha JE, Khattri R, Schmidt KF, Jennings D, VanBrocklin H, Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. Cancer Res 79, 3455&#x2013;3465 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606349</ArticleId><ArticleId IdType="pubmed">31064845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D&#x2019;Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS, A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 77, 2893&#x2013;2902 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505323</ArticleId><ArticleId IdType="pubmed">28572504</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi J, Duan H, Yaghoubi S, Packiasamy J, Huynh L, Lam T, Shaikh F, Behera D, Song H, Blecha J, Jivan S, Seo Y, VanBrocklin HF, Biodistribution of a Mitochondrial Metabolic Tracer, [(18)F]F-AraG, in Healthy Volunteers. Mol Imaging 2022, 3667417 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400547</ArticleId><ArticleId IdType="pubmed">36072652</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, Goldberg SA, Davidson MC, Mathur S, Durstenfeld MS, Spinelli MA, Hoh R, Tai V, Fehrman EA, Torres L, Hernandez Y, Williams MC, Arreguin MI, Ngo LH, Deswal M, Munter SE, Martinez EO, Anglin KA, Romero MD, Tavs J, Rugart PR, Chen JY, Sans HM, Murray VW, Ellis PK, Donohue KC, Massachi JA, Weiss JO, Mehdi I, Pineda-Ramirez J, Tang AF, Wenger MA, Assenzio MT, Yuan Y, Krone MR, Rutishauser RL, Rodriguez-Barraquer I, Greenhouse B, Sauceda JA, Gandhi M, Scheffler AW, Hsue PY, Henrich TJ, Deeks SG, Martin JN, Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis 9, ofab640 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft EB. 2021. &#x201c;CoVariants: SARS-CoV-2 Mutations and Variants of Interest.&#x201d; https://covariants.org/.</Citation></Reference><Reference><Citation>Lee JH, Yim JJ, Park J, Pulmonary function and chest computed tomography abnormalities 6&#x2013;12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res 23, 233 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9446643</ArticleId><ArticleId IdType="pubmed">36068582</ArticleId></ArticleIdList></Reference><Reference><Citation>Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS, Synthesis of 2&#x2019;-deoxy-2&#x2019;-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol 13, 812&#x2013;818 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20838911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CO Jr., Mitchell BS, Ayres M, Eriksson S, Gandhi V, Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 62, 3100&#x2013;3105 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12036920</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti C, Levi J, Huynh TL, Tiret B, Blecha J, Tang R, VanBrocklin H, Chaumeil MM, Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using (18)F-FAraG PET and MRI. J Nucl Med 63, 140&#x2013;146 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717198</ArticleId><ArticleId IdType="pubmed">33837066</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi J, Goth S, Huynh L, Lam T, Huynh TL, Schulte B, Packiasamy JA, (18)F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. J Nucl Med 62, 802&#x2013;807 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8729865</ArticleId><ArticleId IdType="pubmed">33158906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinahan PE, Fletcher JW, Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31, 496&#x2013;505 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026294</ArticleId><ArticleId IdType="pubmed">21147377</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L, Peluso MJ, Long COVID research risks losing momentum - we need a moonshot. Nature 622, 457&#x2013;460 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37853144</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition, A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 22, e102&#x2013;e107 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennet AM, Reynolds CA, Eriksson UK, Hong MG, Blennow K, Gatz M, Alexeyenko A, Pedersen NL, Prince JA, Genetic association of sequence variants near AGER/NOTCH4 and dementia. J Alzheimers Dis 24, 475&#x2013;484 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477600</ArticleId><ArticleId IdType="pubmed">21297263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LC, Almazan G, Cdon, a cell surface protein, mediates oligodendrocyte differentiation and myelination. Glia 64, 1021&#x2013;1033 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26988125</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Franco D, Kalra R, Draper I, Pacak CA, Asakura A, Kang PB, The Notch signaling pathway in skeletal muscle health and disease. Muscle Nerve 66, 530&#x2013;544 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9804383</ArticleId><ArticleId IdType="pubmed">35968817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogasawara M, Nishino I, A review of core myopathy: central core disease, multiminicore disease, dusty core disease, and core-rod myopathy. Neuromuscul Disord 31, 968&#x2013;977 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34627702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakovcevski M, Akbarian S, Di Benedetto B, Pharmacological modulation of astrocytes and the role of cell type-specific histone modifications for the treatment of mood disorders. Curr Opin Pharmacol 26, 61&#x2013;66 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4716874</ArticleId><ArticleId IdType="pubmed">26515273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, Lynn MA, Mekonnen ZA, Yeow AEL, Garcia-Valtanen P, Al-Delfi Z, Gummow J, Ferguson C, O&#x2019;Connor S, Reddi BAJ, Hissaria P, Shaw D, Kok-Lim C, Gleadle JM, Beard MR, Barry SC, Grubor-Bauk B, Lynn DJ, Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 20, 26 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Donatelli J, Henrich TJ, Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang B, Gao H, Gao L, Hua R, Xu JD, ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology. Front Mol Biosci 8, 708336 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8493804</ArticleId><ArticleId IdType="pubmed">34631794</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, Hall E, Herrera M, Parikh P, Guevara-Coto J, Triche TJ, Scott P, Hekmati S, Maglinte D, Chang X, Mora-Rodriguez RA, Mora J, Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol 12, 746021 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K, Natarajan V, Dewar R, Rupert A, Badralmaa Y, Zhai T, Winchester N, Scrimieri F, Smith M, Davis I, Lallemand P, Giglietti A, Hensien J, Buerkert T, Goshu B, Rehm CA, Hu Z, Lane HC, Imamichi H, Long-term persistence of transcriptionally active &#x2018;defective&#x2019; HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy. AIDS 37, 2119&#x2013;2130 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10615727</ArticleId><ArticleId IdType="pubmed">37555786</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube M, Tastet O, Dufour C, Sannier G, Brassard N, Delgado GG, Pagliuzza A, Richard C, Nayrac M, Routy JP, Prat A, Estes JD, Fromentin R, Chomont N, Kaufmann DE, Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4(+) and CD8(+) T cells. Cell Host Microbe 31, 1507&#x2013;1522 e1505 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10542967</ArticleId><ArticleId IdType="pubmed">37708853</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Swank ZN, Goldberg SA, Lu S, Dalhuisen T, Borberg E, Senussi Y, Luna MA, Chang Song C, Clark A, Zamora A, Lew M, Viswanathan B, Huang B, Anglin K, Hoh R, Hsue PY, Durstenfeld MS, Spinelli MA, Glidden DV, Henrich TJ, Kelly JD, Deeks SG, Walt DR, Martin JN, Plasma-based antigen persistence in the post-acute phase of COVID-19. Lancet Infect. Dis. (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38604216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez JJ, Aguilar-Rodriguez BL, Rodriguez L, Hogan LE, Somsouk M, McCune JM, Deeks SG, Laszik ZG, Hunt PW, Henrich TJ, CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals. Pathog Immun 4, 147&#x2013;160 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508427</ArticleId><ArticleId IdType="pubmed">31139759</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LM, Lannigan J, Jaimes MC, OMIP-069: Forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood. Cytometry A 97, 1044&#x2013;1051 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132182</ArticleId><ArticleId IdType="pubmed">32830910</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>